About Scope Biosciences
Scope Biosciences is a company based in Wageningen (Netherlands) founded in 2019 by Stijn Prinsen, Bart Scholten, Niek Savelkoul, and Jurre Steens. Scope Biosciences has raised $1.69 million across 3 funding rounds from investors including European Union, GenDx and Oost NL. Scope Biosciences offers products and services including scope Dx assay and CRISPR-Cas Test. Scope Biosciences operates in a competitive market with competitors including Nanopore, PacBio, Quanterix, Omniome and Complete Genomics, among others.
- Headquarter Wageningen, Netherlands
- Founders Stijn Prinsen, Bart Scholten, Niek Savelkoul, Jurre Steens
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Scope Biosciences B.V.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.69 M (USD)
in 3 rounds
-
Latest Funding Round
$531.52 K (USD), Seed
Oct 25, 2023
-
Investors
European Union
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Scope Biosciences
Scope Biosciences offers a comprehensive portfolio of products and services, including scope Dx assay and CRISPR-Cas Test.
CRISPR-Cas based test for detecting genetic material onsite
Simple onsite tool for healthcare and agriculture genetic analysis
People of Scope Biosciences
Unlock access to complete
Unlock access to complete
Funding Insights of Scope Biosciences
Scope Biosciences has successfully raised a total of $1.69M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $531.52 thousand completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Scope Biosciences
Scope Biosciences has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, GenDx and Oost NL.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sector-agnostic VC firm investing in geographies such as the Netherlands
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Scope Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Scope Biosciences
Investment portfolio details for Scope Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Scope Biosciences
Detailed financials for Scope Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Scope Biosciences Comparisons
Peer comparison for Scope Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Scope Biosciences
Scope Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nanopore, PacBio, Quanterix, Omniome and Complete Genomics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Nanopore-based electronic systems for single-molecule analysis are developed.
|
|
| Locked | Locked | Locked |
Instrument systems and software for single-molecule real-time sequencing are developed.
|
|
| Locked | Locked | Locked |
Assay kits for ultra-sensitive biomarker detection are developed.
|
|
| Locked | Locked | Locked |
Genome sequencing platform is provided for clinical diagnostics.
|
|
| Locked | Locked | Locked |
DNA sequencing platform for human genome analysis is developed.
|
|
| Locked | Locked | Locked |
Handheld diagnostic and sequencing devices are developed for personalized healthcare.
|
Detailed competitors of Scope Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Scope Biosciences
Complete news archive for Scope Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scope Biosciences
Scope Biosciences was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Scope Biosciences is headquartered in Wageningen, Netherlands. It is registered at Wageningen, Gelderland, Netherlands.
Scope Biosciences is a funded company, having raised a total of $1.69M across 3 funding rounds to date.
Scope Biosciences was founded in 2019 in Wageningen, Netherlands. The scopeDx platform is developed using proprietary Type III CRISPR-Cas nucleases. Nucleic acid sequences are detected to identify genetic material with single nucleotide specificity. Operations are centered in the biotechnology sector, focusing on diagnostic tools for research and clinical applications. Co-founders include Stijn Prinsen, Bart Scholten, Niek Savelkoul, and Jurre Steens.
Scope Biosciences offers scope Dx assay and CRISPR-Cas Test.
Scope Biosciences has 4 investors. Key investors include European Union, GenDx, Oost NL, and Tech Transfer.